2024
Heterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas
Tabor J, O'Brien J, Valero S, Pappajohn A, McGuone D, Erson-Omay Z, Yasuno K, Gunel M, Moliterno J. Heterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas. Neurosurgery 2024, 70: 203-203. DOI: 10.1227/neu.0000000000002810_112.Peer-Reviewed Original ResearchProgression-free survivalHigh-grade meningiomasOverall survivalNF2 mutationsDecreased PFSLow grade meningiomasWHO grading criteriaLow-grade meningiomasAssociated with recurrenceSomatic NF2 mutationsHigher recurrence rateSomatic driver mutationsAggressive clinical characteristicsIncreased chromosomal instabilityLoss of CDKN2A/BHigh-copy number variationCDKN2A mutationsCopy number variationsAggressive meningiomasLow-grade onesProliferative indexCDKN2A lossGrade meningiomasRecurrence rateMitotic count
2022
P11.46.A Whole exome sequencing identifies novel SLIT2 mutations in primary CNS lymphoma
Kaulen L, Erson-Omay E, Henegariu O, Karschnia P, Huttner A, Günel M, Baehring J. P11.46.A Whole exome sequencing identifies novel SLIT2 mutations in primary CNS lymphoma. Neuro-Oncology 2022, 24: ii68-ii68. PMCID: PMC9443199, DOI: 10.1093/neuonc/noac174.235.Peer-Reviewed Original ResearchPrimary CNS lymphomaCNS lymphomaOverall survivalExtension cohortEpstein-Barr virus statusKaplan-Meier methodLog-rank testCBio Cancer Genomics PortalReporter luciferase assaysFree survivalShorter OSTumor DNA samplesPCNSL patientsClinical outcomesShorter PFSSomatic insertions/deletionsVirus statusFavorable outcomeLymphoid malignanciesClinical observationsTumor tissuePersonalized careCDKN2A lossCopy number alterationsCohort